Automate Your Wheel Strategy on ILMN
With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Here's Why Illumina (ILMN) is a Strong Value Stock
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth of the Alliance for Genomic Discovery (AGD or the Alliance). With the addition of Regeneron Genetics Center® (RGC®) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes.
Read More
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University (FSU) College of Medicine, further driving innovation in diagnostics and treatments for rare diseases. "An estimated 30 million people across the country are living with a rare disease today and clinical whole-genome testing provides a transformative opportunity to …
Read More
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Negative
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.
Read More
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
Published: February 25, 2026 by: PRNewsWire
Sentiment: Neutral
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis.
Read More
Illumina launches TruPath Genome, setting a new standard in genomic insight
Published: February 24, 2026 by: PRNewsWire
Sentiment: Neutral
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology" SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of …
Read More
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 …
Read More
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Illumina To Webcast Upcoming Investor Conference
Published: February 17, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference TD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026 The fireside chat is scheduled for 12:10pm PT (3:10pm ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
Read More
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.
Read More
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally
Published: February 03, 2026 by: PRNewsWire
Sentiment: Neutral
Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom.
Read More
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.
Read More
Illumina completes acquisition of SomaLogic
Published: January 30, 2026 by: PRNewsWire
Sentiment: Neutral
Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.
Read More
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
REGN or ILMN: Which Is the Better Value Stock Right Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Illumina Gets Medicare Boost for Cancer Test, Shares Climb
Published: January 20, 2026 by: Benzinga
Sentiment: Positive
Illumina Inc. (NASDAQ: ILMN) shares are up on Tuesday following news that the company has secured reimbursement for its FDA-approved TruSight Oncology Comprehensive test.
Read More
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Published: January 20, 2026 by: PRNewsWire
Sentiment: Neutral
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. The reimbursement decision from the Centers for Medicare and Medicaid Services (CMS) will expand access to comprehensive genomic profiling (CGP) and the growing role of personalized genomics in oncology care.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Illumina unveils dataset to speed up AI-powered drug discovery
Published: January 13, 2026 by: Reuters
Sentiment: Positive
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.
Read More
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Published: January 13, 2026 by: PRNewsWire
Sentiment: Neutral
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.
Read More
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Read More
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
REGN vs. ILMN: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
About Illumina, Inc. (ILMN)
- IPO Date 2000-07-28
- Website https://www.illumina.com
- Industry Medical - Diagnostics & Research
- CEO Jacob Thaysen
- Employees 8970